NCT04544111View on ClinicalTrials.gov

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 2, 2020

Primary Completion Date

September 2, 2026

Study Completion Date

September 2, 2026

Conditions
Thyroid CancerThyroid Cancer, FollicularPapillary Thyroid CancerFollicular Thyroid CancerHurthle Cell TumorPoorly Differentiated Thyroid Gland CarcinomaHurthle Cell Thyroid Neoplasia
Interventions
DRUG

Trametinib

"2mg by mouth daily~\*If patient loses the ability to swallow while on study, trametinib may be provided as a powder in bottle for reconsititution. Trametinib, as a powder in bottle, will be mixed with sterile/purified water into an oral solution and administered PO or through enteral feeding tube"

DRUG

Dabrafenib

150 mg twice daily (OR at dose the patient previously tolerated)

DRUG

PDR001

400mg IV every 4 weeks

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (Limited protocol activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited protocol activities), Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown

07645

Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER